載入中
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
前收盤價
US$2.545
−US$0.015 · -0.59%
盤後
US$2.545
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
日內區間
目前US$2.545
52週區間
目前US$2.545
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
12
估值過高
情緒
53
多空交錯
風險
58
風險偏高
動能
39
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
日內區間
目前US$2.545
52週區間
目前US$2.545
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.33
上漲空間 580.94%價格歷史記錄不可用
最高：US$20.00平均的：US$17.33最低：US$16.00報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
